Top

Published in:

01-04-2012 | Review Article

Duration of Anticoagulation After Cerebral Venous Sinus Thrombosis

Authors: Frances Caprio, Richard A. Bernstein

Published in: Neurocritical Care | Issue 2/2012

Abstract

Cerebral venous sinus thrombosis (CVST) often occurs in young patients and is treated with acute and then long-term oral anticoagulation. It is important to decide when to discontinue anticoagulation, as lifelong anticoagulation exposes the patient to considerable cumulative risk. However, a lack of high quality studies makes choosing a duration of anticoagulation after CVST difficult. In this article, we review the evidence for different treatment durations in several common clinical scenarios of CVST. In addition, when no direct evidence is available, we discuss and extrapolate from the more comprehensively studied situation of systemic venous thromboembolic disease. Recommendations are graded using standard criteria for the level of evidence.

Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, de Veber G, Ferro JM, Tsai FY. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:1158–92.PubMedCrossRef

Stam J, de Bruijn SF, deVeber G. Anticoagulation for cerebral sinus thrombosis. Cochrane Database Syst Rev. 2002;(4):CD002005.

Einhäupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M, Haberl RL, Pfister HW, Schmiedek P. Heparin treatment in sinus venous thrombosis. Lancet. 1991;338:597–600.PubMedCrossRef

de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular weight heparin for cerebral sinus thrombosis. Stroke. 1999;30:484–8.PubMedCrossRef

Preter M, Tzourio C, Ameri A, Bousser MG. Long-term prognosis in cerebral venous thrombosis: follow-up of 77 patients. Stroke. 1996;27:243–6.PubMedCrossRef

Brucker AB, Vollert-Rogenhofer H, Wagner M, Stieglbauer K, Felber S, Trenkler J, Deisenhammer E, Aichner F. Heparin treatment in acute cerebral sinus venous thrombosis: a retrospective clinical and MR analysis of 42 cases. Cerebrovasc Dis. 1998;8:331–7.PubMedCrossRef

Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin. 1992;10:87–111.PubMed

Strupp M, Covi M, Seelos K, Dichgans M, Brandt T. Cerebral venous thrombosis: correlation between recanalization and clinical outcome: a long-term follow-up of 40 patients. J Neurol. 2002;249:1123–4.PubMedCrossRef

Stolz E, Trittmacher S, Rahimi A, Gerriets T, Röttger C, Siekmann R, Kaps M. Influence of recanalization on outcome in dural sinus thrombosis: a prospective study. Stroke. 2004;35:544–7.PubMedCrossRef

10.

Baumgartner RW, Studer A, Arnold M, Georgiadis D. Recanalisation of cerebral venous thrombosis. J Neurol Neurosurg Psychiatry. 2003;74:459–61.PubMedCrossRef

11.

Röttger C, Trittmacher S, Gerriets T, Blaes F, Kaps M, Stolz E. Reversible MR imaging abnormalities following cerebral venous thrombosis. AJNR Am J Neuroradiol. 2005;26:607–13.PubMed

12.

Nagaraja D, Rao BSS, Taly AB. Randomized controlled trial of heparin in therapy of cerebral venous/sinus thrombosis. Nimhans J. 1995;13:111–5.

13.

Ferro JM, Canhão P, Stam J, Bousser MG. Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664–70.PubMedCrossRef

14.

Ferro JM, Correia M, Pontes C, Baptista MV, Pita F. Cerebral Venous Thrombosis Portuguese Collaborative Study Group (Venoport). Cerebral vein and dural sinus thrombosis in Portugal: 1980–1998. Cerebrovasc Dis. 2001;11:177–82.PubMedCrossRef

15.

Stolz E, Rahimi A, Gerriets T, Kraus J, Kaps M. Cerebral venous thrombosis: an all or nothing disease? Prognostic factors and long-term outcome. Clin Neurol Neurosurg. 2005;107:99–107.PubMedCrossRef

16.

Girot M, Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, Leys D. ISCVT investigators. Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage. Stroke. 2007;38:337–42.PubMedCrossRef

17.

Masuhr F, Mehraein S, Einhäupl K. Cerebral venous and sinous thrombosis. J Neurol. 2004;251:11–23.PubMedCrossRef

18.

Ferro JM, Lopes MG, Rosas MJ, Ferro MA, Fontes J. Cerebral Venous Thrombosis Portuguese Collaborative Study Group. Long-term prognosis of cerebral vein and dural sinus thrombosis: results of the VENOPORT study. Cerebrovasc Dis. 2002;13:272–8.PubMedCrossRef

19.

Maqueda VM, Thijs V. Risk of thromboembolism after cerebral venous thrombosis. Eur J Neurol. 2006;13:302–5.PubMedCrossRef

20.

Gosk-Bierska I, Wysokinski W, Brown RD Jr, Karnicki K, Grill D, Wiste H, Wysokinska E, McBane RD 2nd. Cerebral venous sinus thrombosis: incidence of venous thrombosis recurrence and survival. Neurology. 2006;67:814–9.PubMedCrossRef

21.

Martinelli I, Bucciarelli P, Passamonti SM, Battaglioli T, Previtali E, Mannucci PM. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation. 2010;121:2740–6.PubMedCrossRef

22.

Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) [published correction appears in Chest 2008;134:892]. Chest. 2008;133(6 suppl):454S–545S.

23.

Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet. 1992;340:873–6.

24.

Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995;74:606–11.PubMed

25.

Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332:1661–5.PubMedCrossRef

26.

Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001;103:2453–60.PubMed

27.

Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep vein thrombosis. N Engl J Med. 2001;345:165–9.PubMedCrossRef

28.

Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003;139:19–25.PubMed

29.

Campbell IA, Bentley DP, Prescott RJ, et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomized trial. BMJ. 2007;334:674–80.PubMedCrossRef

30.

Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901–7. (LAFIT).PubMedCrossRef

31.

Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425–34. (PREVENT).PubMedCrossRef

32.

Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 1997;336:393–8. (DURAC 2).PubMedCrossRef

33.

Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355:1780–9. (PROLONG).PubMedCrossRef

34.

Cosmi B, Legnani C, Tosetto A, et al. Use of Ddimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. J Thromb Thrombolysis. 2009;28:381e8.CrossRef

35.

Ost D, Tepper J, Mihara H, et al. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA. 2005;294:706e15.

36.

Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631–9.PubMedCrossRef

37.

Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(suppl):257S–98S.PubMedCrossRef

38.

Kearon C. Long-term anticoagulation for venous thromboembolism: duration of treatment and management of warfarin therapy. Clin Chest Med. 2010;31(4):719–30.PubMedCrossRef

39.

Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245–6.PubMedCrossRef

40.

Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809–15.PubMedCrossRef

41.

Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 suppl):381S–453S.PubMedCrossRef

42.

Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362:523–6.PubMedCrossRef

43.

Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293:2352–61.PubMedCrossRef

44.

Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;81:14–7.PubMed

45.

Eichinger S, Pabinger I, Stümpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without Factor V Leiden. Thromb Haemost. 1997;77:624–8.PubMed

46.

Ho WK, Hankey GJ, Quinlan DJ, et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006;166:729–36.PubMedCrossRef

47.

Lindmarker P, Schulman S, Sten-Linder M, et al. The risk of recurrent venous thromboembolism in carriers and noncarriers of the G1691A Allele in the coagulation factor V gene and the G20210A Allele in the prothrombin gene. Thromb Haemost. 1999;81:684–9.PubMed

48.

Miles JS, Miletich JP, Goldhaber SZ, et al. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol. 2001;37:215–8.PubMedCrossRef

49.

Palareti G, Legnani C, Cosmi B, et al. Predictive value of d-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation. 2003;108:313–8.PubMedCrossRef

50.

Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800–2.PubMed

51.

Simioni P, Prandoni P, Lensing AW, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood. 2000;96:3329–33.PubMed

52.

Murin S, Marelich GP, Arroliga AC, Matthay RA. Hereditary thrombophilia and venous thromboembolism. Am J Respir Crit Care Med. 1998;158:1369.PubMed

53.

Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol. 2008;143:321.PubMedCrossRef

54.

Coppens M, Reijnders JH, Middeldorp S, et al. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost. 2008;6:1474.PubMedCrossRef

55.

Koeleman BP, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol. 1997;34:256.PubMed

56.

Makris M, Preston FE, Beauchamp NJ, et al. Co-inheritance of the 2012A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost. 1997;78:1426.PubMed

57.

Meinardi JR, Middeldorp S, de Kam PJ, et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol. 2002;116:625.PubMedCrossRef

58.

Lijfering WM, Brouwer JL, Veeger NJ, Bank I, Coppens M, Middeldorp S, Hamulyák K, Prins MH, Büller HR, van der Meer J. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood. 2009;113:5314–22.PubMedCrossRef

59.

de Freitas GR, Bogousslavsky J. Risk factors of cerebral vein and sinus thrombosis. Front Neurol Neurosci. 2008;23:23–54.PubMed

60.

Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793–7.PubMedCrossRef

61.

Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002;70:126–32.PubMedCrossRef

62.

Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood. 2006;107:2766–73.PubMedCrossRef

63.

Reuner KH, Ruf A, Grau A, Rickmann H, Stolz E, Jüttler E, Druschky KF, Patscheke H. Prothrombin gene G202103A transition is a risk factor for cerebral venous thrombosis. Stroke. 1998;29:1765–9.PubMedCrossRef

64.

Einhäupl K, Stam J, Bousser MG, de Bruijn SF, Ferro JM, Martinelli I. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol. 2010;17:1229–35.PubMedCrossRef

65.

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.PubMedCrossRef

66.

Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, Khamashta MA, Shoenfeld Y, Catastrophic Antiphospholipid Syndrome Registry Project Group. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530–4.PubMedCrossRef

67.

Schulman S, Svenungsson E, Granqvist S, Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med. 1998;104:332–8.PubMedCrossRef

68.

Gadelha T, André C, Jucá AA, Nucci M. Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis. Cerebrovasc Dis. 2005;19:49–52.PubMedCrossRef

69.

Bergendal A, Odlind V, Persson I, Kieler H. Limited knowledge on progestogen-only contraception and risk of venous thromboembolism. Acta Obstet Gynecol Scand. 2009;88(3):261–6.PubMedCrossRef

70.

Hannaford PC. Epidemiology of the contraceptive pill and venous thromboembolism. Thromb Res. 2011;127(Suppl 3):S30–4.PubMedCrossRef

71.

Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke. 2008;39:2644–91.PubMedCrossRef

72.

Davie CA, O’Brien P. Stroke and pregnancy. J Neurol Neurosurg Psychiatry. 2008;79:240–5.PubMedCrossRef

73.

Wilterdink JL, Easton JD. Cerebral ischemia in pregnancy. Adv Neurol. 2002;90:51–62.PubMed

74.

Lanska DJ, Kryscio RJ. Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke. 2000;31:1274–82.PubMedCrossRef

75.

James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol. 2005;106:509–16.PubMedCrossRef

76.

Françcois P, Fabre M, Lioret E, Jan M. Vascular cerebral thrombosis during pregnancy and post-partum. Neurochirurgie. 2000;46:105–9.

77.

Lanska DJ, Kryscio RJ. Peripartum stroke and intracranial venous thrombosis in the National Hospital Discharge Survey. Obstet Gynecol. 1997;89:413–8.PubMedCrossRef

78.

Bates S, Greer I, Pabinger I, Sofaer S, Hirsch J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: evidence-based clinical practice guidelines (8th edition). Chest. 2008;133:844S–86S.PubMedCrossRef

79.

Pabinger I, Grafenhofer H, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K, Kaider A. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood. 2002;100:1060–2.PubMedCrossRef

80.

Lamy C, Hamon JB, Coste J, Mas JL, French Study Group on Stroke in Pregnancy. Ischemic stroke in young women: risk of recurrence during subsequent pregnancies. Neurology. 2000;55:269–74.PubMed

81.

Mehraein S, Ortwein H, Busch M, Weih M, Einhäupl K, Masuhr F. Risk of recurrence of cerebral venous and sinus thrombosis during subsequent pregnancy and puerperium. J Neurol Neurosurg Psychiatry. 2003;74:814–6.PubMedCrossRef

82.

Srinivasan K. Cerebral venous and arterial thrombosis in pregnancy and puerperium: a study of 135 patients. Angiology. 1983;34:731–46.PubMedCrossRef

Title: Duration of Anticoagulation After Cerebral Venous Sinus Thrombosis
Authors: Frances Caprio
Richard A. Bernstein
Publication date: 01-04-2012
Publisher: Humana Press Inc
Published in: Neurocritical Care / Issue 2/2012
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI: https://doi.org/10.1007/s12028-011-9661-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Duration of Anticoagulation After Cerebral Venous Sinus Thrombosis

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Increased Rate of Aspiration Pneumonia and Poor Discharge Outcome Among Acute Ischemic Stroke Patients Following Intubation for Endovascular Treatment

Subacute Seizure Incidence in Thrombolysis-treated Ischemic Stroke Patients

A Case–Control Study of Stroke Risk Factors and Outcomes in African American Stroke Patients With and Without Crack–Cocaine Abuse

Orthostatic Hypotension Following Resection of a Dorsal Medullary Hemangioblastoma

Critical Thresholds for Cerebrovascular Reactivity After Traumatic Brain Injury

Head Computed Tomography Scanning During Pediatric Neurocritical Care: Diagnostic Yield and the Utility of Portable Studies